| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income (loss) | 2,222 | 1,467 | 672 | 1,284 |
| Depreciation and amortization | 1,003 | 661 | 325 | 921 |
| Deferred and prepaid income taxes | 20 | -49 | 41 | 10 |
| Stock-based compensation expense | 228 | 149 | 74 | 197 |
| Goodwill and other intangible asset impairment charges | 46 | 46 | - | 276 |
| Net loss (gain) on investments and notes receivable | 181 | 191 | -28 | -60 |
| Contingent consideration net expense (benefit) | 11 | 0 | 5 | -4 |
| Inventory step-up amortization | 127 | 118 | 81 | 0 |
| Fixed asset impairment | 73 | - | - | - |
| Other, net | 22 | 72 | -7 | 22 |
| Trade accounts receivable | 171 | 139 | 107 | 261 |
| Inventories | 138 | 44 | 109 | 274 |
| Other assets | 103 | 108 | 77 | 109 |
| Accounts payable, accrued expenses and other liabilities | 11 | -154 | -385 | -142 |
| Cash provided by (used for) operating activities | 3,170 | 1,827 | 541 | 1,979 |
| Purchases of property, plant and equipment and internal use software | 525 | 344 | 187 | 513 |
| Proceeds from sale of property, plant and equipment | - | - | - | 1 |
| Payments for acquisitions of businesses, net of cash acquired | 1,504 | 1,248 | 239 | 1,222 |
| Payments for investments and acquisitions of certain technologies | 180 | 110 | 77 | 264 |
| Proceeds for settlements of hedge contracts | 69 | 69 | - | - |
| Other, net | -11 | -7 | -3 | -16 |
| Proceeds from settlements of hedge contracts | - | - | - | 0 |
| Cash provided by (used for) investing activities | -2,128 | -1,626 | -500 | -1,983 |
| Payment of contingent consideration previously established in purchase accounting | 62 | 62 | 0 | 131 |
| Payments for royalty rights | - | - | 10 | 26 |
| Payments for finance leases | 49 | 42 | 36 | 25 |
| Payments on short-term borrowings | 1,595 | 1,583 | 1,083 | 504 |
| Proceeds from short-term borrowings, net of debt issuance costs | - | - | - | 22 |
| Net increase (decrease) in commercial paper | -196 | - | -192 | 0 |
| Proceeds from long-term borrowings, net of debt issuance costs | 1,558 | 1,558 | 1,558 | 2,145 |
| Cash dividends paid on preferred stock | - | - | - | 0 |
| Cash used to net share settle employee equity awards | 128 | 123 | 118 | 83 |
| Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans | 262 | 147 | 115 | 202 |
| Other, net | -2 | -1 | - | - |
| Cash provided by (used for) financing activities | -211 | -107 | 233 | 1,600 |
| Effect of foreign exchange rates on cash | 39 | 41 | 39 | -2 |
| Net increase (decrease)in cash, cash equivalents, restricted cash and restricted cash equivalents | 870 | 135 | 314 | 1,594 |
| Cash and cash equivalents at beginning of period | 606 | 606 | 606 | 1,055 |
| Cash and cash equivalents at end of period | 1,476 | 741 | 919 | 2,649 |
BOSTON SCIENTIFIC CORP (BSX)
BOSTON SCIENTIFIC CORP (BSX)